s****e
发帖数: 34 | 1 【 以下文字转载自 Stock 讨论区 】
发信人: dragonfly (小蜻蜓), 信区: Stock
标 题: 翻倍机会：ACRX
发信站: BBS 未名空间站 (Fri Oct 12 11:48:23 2018, 美东)
下周开始暴涨，11月3号正式出消息再飚一波
估计月内翻番没问题，以后翻番几会多多。
抓紧建仓。
REDWOOD CITY, Calif., Oct. 12, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (ACRX), (AcelRx), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for use in a
medically supervised setting, today announced that NASDAQ has halted trading
of the company's common stock.
The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug
Products Advisory Committee (AADPAC) is meeting today to review AcelRx's New
Drug Application (NDA) for DSUVIA, a 30 mcg sufentanil sublingual tablet
for the management of moderate-to-severe acute pain in adult patients in a
medically supervised setting.
The Advisory Committee meeting is scheduled from 8:00 a.m. to 5:00 p.m. ET.
The briefing materials can be found on the FDA website. The Prescription
Drug User Fee Act (PDUFA) date for completion of the review of the company's
NDA for DSUVIA is November 3, 2018. |
|
